Based in the United States, XenImmune is a startup.
XenImmune develops immuno-oncology therapies that use a proprietary antibody-enzyme fusion protein to 'paint' tumors with foreign glyco-antigens, triggering the immune system to recognize and reject cancer cells by mimicking organ transplant hyperacute rejection.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.